Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
Provider: Stock Traders Daily
Provider: MacroRisk Analytics/EconomicInvestor
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Meridian Bioscience Inc lowers FY 2014 outlook

Thursday, 24 Apr 2014 07:30am EDT 

Meridian Bioscience Inc:Expects FY 2014 net sales to be in the range of $190-$195 mln, compared to previous range of $203-$208 mln.Expects FY 2014 per share diluted earnings to be between $0.85 and $0.90, compared to previous range of $0.98 and $1.03.FY 2014 revenue of $201 mln, EPS of $0.97 - Thomson Reuters I/B/E/S. 

Company Quote

4:00pm EDT